Due to the stepping down of the Board Chair and the desire to accelerate our focus of increasing awareness and improving New Zealand’s Bone Health, Osteoporosis New Zealand has two vacancies available on the Trust Board.

Osteoporosis New Zealand (ONZ) is delighted to advise that Pharmac has decided to fund denosumab (Prolia) in NZ for the treatment of severe, established osteoporosis, subject to certain clinical criteria being met.